Current Environment:

Research & Innovation | Overview

Clinicians in the Boston Children’s Pediatric Pulmonary Hypertension Program have contributed in many ways to new developments in this rapidly advancing field. These contributions include:

  • early investigations of inhaled nitric oxide to treat pulmonary hypertension (PH)
  • participation in clinical trials of medications to treat PH, including sildenafil, ambrisentan and treprostinil, and Orenitram
  • use of the intravascular Potts procedure to treat severe PH
  • use of the extra-corporeal membrane oxygenator as a bridge to lung transplant
  • participating in scientific and teaching conferences in the U.S. and internationally

Recent clinical trials include:

  • A multicenter, open label, 24-week uncontrolled study to evaluate the safety, tolerability and pharmacokinetics of oral Treprostinil extended release tablets following transition from remodulin or inhaled prostacyclin therapy or as add-on to current PAH therapy in de novo prostacyclin pediatric subjects aged 7 to 17 years with pulmonary arterial hypertension (TED-PH-206).
  • Intravenous remodulin (treprostinil) as add-on therapy for the treatment of persistent pulmonary hypertension of the newborn: a randomized, placebo-controlled, safety and efficacy study (RIV-PN-201).
  • Data-fusion- A Self-Scaling, Open Source Registry Advancing Pediatric Pulmonary Vascular Disease Research
  • Scalable Collaborative Infrastructure for a Learning Healthcare System
  • TOPP-2 International Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension Registry

Recent research and publications include:

Krishnan U, Feinstein JA, Adatia I, Austin ED, Mullen MP, Hopper RK, Hanna B, Romer L, Keller RL, Fineman J, Steinhorn R, Kinsella JP, Ivy DD, Rosenzweig EB, Raj U, Humpl T, Abman SH; Pediatric Pulmonary Hypertension Network (PPHNet). “Evaluation and Management of Pulmonary Hypertension in Children with Bronchopulmonary Dysplasia.Journal of Pediatrics. 2017, Jun 20.

Geva A, Gronsbell JL, Cai T, Cai T, Murphy SN, Lyons JC, Heinz MM, Natter MD, Patibandla N, Bickel J, Mullen MP, Mandl KD; Pediatric Pulmonary Hypertension Network and National Heart, Lung, and Blood Institute Pediatric Pulmonary Vascular Disease Outcomes Bioinformatics Clinical Coordinating Center Investigators. A Computable Phenotype Improves Cohort Ascertainment in a Pediatric Pulmonary Hypertension Registry. Journal of Pediatrics. 2017, Jun 15.

Ong MS, Mullen MP, Austin ED, Szolovits P, Natter M, Geva A, Cai T, Kong SW, Mandl KD. “Learning a Comorbidity-Driven Taxonomy of Pediatric Pulmonary Hypertension.Circulation Research. 2017, Jun 13.

Kulik TJ, Austin ED. “Pulmonary hypertension's variegated landscape: a snapshot.Pulmonary Circulation. 2017, Mar 13; 7(1): 67-81

Mullen MP, Kulik TJ. “Pulmonary Hypertension in Children: Classification, Evaluation, and Diagnosis,” and “Pulmonary Hypertension in Children: Management and Prognosis.” UpToDate. 2017.

Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj JU, Cornfield D, Stenmark KR, Steinhorn R, Thebaud B, Fineman JR, Kuehne T, Feinstein JA, Friedberg MK, Earing M, Barst RJ, Keller RL, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel DL, American Heart Association Council on Cardiopulmonary CCP, Resuscitation, Council on Clinical C, Council on Cardiovascular Disease in the Y, Council on Cardiovascular R, Intervention, Council on Cardiovascular S, Anesthesia, the American Thoracic S. “Pediatric Pulmonary Hypertension. Guidelines from the American Heart Association and American Thoracic Society.Circulation. 2015; 132:2037-2099

Mullen MP, Andrus J, Labella MH, Forbes PW, Rao S, Harris JE, Kulik TJ, DeMaso DR. “Quality of Life and Parental Adjustment in Pediatric Pulmonary Hypertension.Chest. 2014; 145(2): 237-244.